• Néovacs’ board decided to reduce capital to absorb losses, as announced on October 19, 2026.
• The nominal value per share falls from EUR 1 to EUR 0.05.
• Share capital decreases from EUR 1.82 million to EUR 91,083.80, remaining divided into 1,821,676 shares.
• The decision implements the ninth resolution adopted at the October 16, 2026 general meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neovacs SA published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.